Archive: 04/06/2019
Lymphoma trial finds combination targeted therapy effective prior to chemotherapy
Results of a Phase II clinical trial conducted at The University of Texas MD Anderson Cancer Center revealed that combination targeted therapy, consisting of rituximab, lenalidomide and ibrutinib (RLI), had an 84.6 percent ...
Jun 4, 2019